This stock is no longer traded. It was delisted on September 2, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing oral therapies for rare endocrine diseases and endocrine-related tumors. The company’s current portfolio centers on medicines designed to address conditions driven by hormone dysregulation, with a particular emphasis on acromegaly, carcinoid syndrome, and congenital adrenal hyperplasia. Its lead product, PALSONIFY (paltusotine), is an oral selective somatostatin receptor agonist used in endocrine care, while atumelnant is being developed as an investigational therapy for adrenal-related disorders. Based in San Diego, California, Crinetics Pharmaceuticals operates at the intersection of endocrinology and specialty drug development, serving a market that relies on targeted treatments for complex, underserved rare diseases.
Website6055 Lusk Boulevard
San Diego, CA, 92121
United States
The latest articles about CRNX.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals. The deal gives the company immediate exposure to the endocrinology market and provides a new commercial platform beyond its established cystic fibrosis franchise. Vertex Expands Into Endocrinology On September 3, Citigroup […]
Summary of Jul 8's posts. Generated by AI.
Summary of Jul 7's posts. Generated by AI.
The completed acquisition adds PALSONIFY and atumelnant to Vertex’s portfolio, with the two therapies carrying combined peak annual revenue potential of more than $5 billion according to the company. Key Investor TakeawaysVertex Pharmaceuticals (NASDAQ:VRTX) completed its approximately $10 billion equity-value acquisition of Crinetics Pharmaceuticals on September 1, 2026.
Summary of Jan 7's posts. Generated by AI.
Investors talking about CRNX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.